Fulgent Genetics sees FY25 EPS (65c), consensus (46c)

Sees FY25 core revenue $310M, consensus $324.21M. Paul Kim, CFO, said, “We are pleased with our financial performance in 2024 and believe we have entered 2025 in a position of strength, with projected growth in our laboratory services business and a strong balance sheet to execute our objectives.”